IL39167A - X-ray shading agents containing a water soluble salt of 3-acetamido-5-hydroxy-acetamido-2,4,6-triiodobenzoic acid - Google Patents
X-ray shading agents containing a water soluble salt of 3-acetamido-5-hydroxy-acetamido-2,4,6-triiodobenzoic acidInfo
- Publication number
- IL39167A IL39167A IL39167A IL3916772A IL39167A IL 39167 A IL39167 A IL 39167A IL 39167 A IL39167 A IL 39167A IL 3916772 A IL3916772 A IL 3916772A IL 39167 A IL39167 A IL 39167A
- Authority
- IL
- Israel
- Prior art keywords
- salt
- agent
- ray shading
- water
- base
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract 23
- 239000003795 chemical substances by application Substances 0.000 title claims 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims 13
- YBOGFJDGQDTTGW-UHFFFAOYSA-N acetamido 3-acetamido-5-hydroxy-2,4,6-triiodobenzoate Chemical compound C(C)(=O)NC=1C(=C(C(=O)ONC(C)=O)C(=C(C1I)O)I)I YBOGFJDGQDTTGW-UHFFFAOYSA-N 0.000 title claims 2
- 239000002253 acid Substances 0.000 claims abstract 8
- 239000000203 mixture Substances 0.000 claims abstract 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000007864 aqueous solution Substances 0.000 claims abstract 4
- KISFRFNQZTVXGT-UHFFFAOYSA-N 3-acetamido-5-[(2-hydroxyacetyl)amino]-2,4,6-triiodobenzoic acid Chemical compound CC(=O)NC1=C(I)C(NC(=O)CO)=C(I)C(C(O)=O)=C1I KISFRFNQZTVXGT-UHFFFAOYSA-N 0.000 claims abstract 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims abstract 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 18
- 238000000034 method Methods 0.000 claims 15
- 239000000243 solution Substances 0.000 claims 8
- 238000009608 myelography Methods 0.000 claims 3
- 238000007487 urography Methods 0.000 claims 3
- 238000002583 angiography Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 230000001954 sterilising effect Effects 0.000 claims 2
- -1 N-methylglucamine salt Chemical class 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims 1
- 239000000920 calcium hydroxide Substances 0.000 claims 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1391843 Radiopaque composition SCHERING AG 10 April 1972 [10 April 1971] 16346/72 Heading A5B An X-ray contrast composition comprises an aqueous solution of at least one watersoluble, physiologically-tolerable salt of 3-acetamido-5-hydroxyacetamido-2, 4, 6-triiodobenzoic acid, the salt(s) being present in an amount equivalent to 19.8-74.4g. of the acid per 100 ml of the composition. The salt may be a sodium, calcium, ethanolamine or N- methyl glucamine salt. The composition may also include disodium ethylene diamine tetraacetic acid salt. It may be enclosed in capsules.
[GB1391843A]
Claims (3)
1. What we claim is: I 1. A process for the production of X-ray shading agents containing the water soluble salts of 3^cetaniido-5-2iydroxyaceta do-2,4»6-triiodobeiizoic acid and a physiologically acceptable base comprising the steps of dissolving per 100 ml of water about 19*8 to about 74*4 g of 3- acet-amido-5-hydroxyacetamido-2,4,6-triiodobenzoie acid and the equivalent quantity of one or more physiologically acceptable bases filing the solution in ampoules or multivials and then sterilizing the same.
2. A process according to claim 1 wherein N-methlglucamine is used as the physiologically acceptable base.
3. A process according to claim 1 wherein sodium hydroxide is used as the physiologically acceptable base. 4· A process according to claim 1 wherein a mixture of N-methylglucamine and sodium hydroxide are used as the physiologically acdeptable base. 5. An X-ray shading agent which comprises an aqueous solution of a water-soluble salt of ^cei¾tmido-5-hydrozyacetanddo-2,4#6-triiodo-benzoic acid with a physiologically tolerable base, the salt being present in the agent in an amount that is equivalent to 19*8 to 74.4 g of ^cetajrido-5-hydroxyacetaniido—2,4»6-tidiodobenzoic acid per 100 ml of water contained in the agent. 6. An X-ray shading agent as claimed in claim 5» wherein the salt is present in the agent in an amountyihat is equivalent to 33*0 to 66.1 g of 3-acetamido-^hydroxyacetamido-2, ,6-triiodobenzoic acid per 100 ml of water contained in the agent. 7. An X-ray shading agent as claimed in cl im 5 or 6, wherein the physiologically tolerable base is an li-methylglucaaine. 8,1 An X-ray shading agent as claimed in claim 5 or 6, wherein the physiologically tolerable base is a calcium hydroxide. 9. An X-ray shading agent as claimed in claim 5 or 6, wherein the physiologically tolerable base is a sodium hydroxide* 10. An X-ray shading agent as claimed in claim 5 or 6, wherein the physiologically tolerable base is a mixture of U-methylglucamine and sodium hydroxide. 11. An X-ray shading agent as claimed in claim 5 or 6, wherein the physiologically tolerable base is an ethanolamlne. 12. An X-ray shading agent as claimed in claim 5, which comprises two or more water-soluble salts of 3-acetamido-5-hydroxyacetamido-2,4,6-triiodobenzoic acid, each salt being a salt with a physiologically tolerable base and the salts being present in the agent in a total amount that is equivalent to 19.8 to 74.4 g of 3-acetamido-5-hydroxy-acetamido-2 , 4 , 6-triiodobenzoic acid per 100 ml of water contained in the agent. 3· An X-ray shading agent as claimed in claim 12, wherein the total amount is equivalent to 33·0 to 66·† g of ^cetanddo-5-hydrozyacetamido-2,4, 6-triiodobenzoic acid per 100 ml of water contained in the agent. 14· An X-ray shading agent as claimed in claim 12 or 13, wherein the salts are a sodium salt and an M^ethylglucamine salt* 15. An X-ray shading agent as claimed in any one of claims 5 to 14» which is in a form suitable for use in urography, angiography or myelography. 16· An X-ray shading agent as claimed in c m 5, and having a composition substantially as described in Example 3 or 4 herein. 17. A process for the manufacture of an X-ray shading agent, wherein ^cetajnido-5-bydroxyacetafflido-2, » 6-triiodobenzoic acid and a physiologically tolerable base capable of forming a water-soluble salt with the acid are dissolved in water and the resulting solution is sterilized, the 3-acetamido— 5-hydroxyacetamido-2 , 4 » 6-triiodobenzoc acid being used in an amount within the range of from 19.8 to 74*4 g per TOO ml of the water used and the base 18. A process as claimed in claim 17» wherein the solution,is introduced into an ampoule or multivial before the sterilization. 19· A process as claimed in claim 17 or 18, wherein the -acetamido-5-hydroxacetainid.o-2,4»6-triiodobenzoic acid is used in an amount within the range of from 33.0 to 66.1 g per 100 ml of the water used. 20. A process as claimed in any one of claims 17 to 19» wherein the physiologically tolerable base is NHnetnylglucamlne. 21. A process as claimed in any one of claims 17 to 19* wherein the physiologically tolerable base is sodium hydroxide. 22. A process as claimed in any one of claims 17 to 19» wherein the physiologically tolerable base is c%cium hydroxide. 23· A process as claimed in any one of claims 17 to 19» wherein the physiologically tolerable base is ethanolamine. 24» A process as claim d in any one of claims 17 to 19» wherein 3* aceamdo-^hydroxyacetamido-2, 4 , 6-triiodobenzoic acid and two or more physiologically tolerable bases are dissolved in the water* each of the bases being capable of forming a water-soluble salt with the acid and the bases being used in a total amount that is equivalent to the amount of the 5-acetand.do-5-hydroxyacetaiiiido-2 , 4 » 6-triiodobenzoic acid used. 25. A process as claimed in claim 24» wherein the bases are H-methyl-^ucamie and sodium hydroxide. 26. A process as claimed in any one of claims 17 to 24» wherein the solution is made up into a form suitable for use in urography, antiography or myelography. 27. A process as claimed in claim 17, conducted substantially as described in Example 3 or 4 herein* 28. An X-ray shading system comprising a water-soluble salt of 3~ acetamido-5-l^droxyacetafflido-2,4,6-triiodobe-izoic acid with a physiologically tolerable base, together with instructions for the administration thereof. which instructions comprise the administration of an aqueous solution of the salt, the salt being present in the solution in an amount that is equivalent to 19*8 to 74.4 g of ^ceta do-5-hdroxyacetaniido-2,4,6-triiodobenzoic acid per 100 ml of water contained in the solution. 29. A X-ray shading system as claimed in claim 28, wherein the salt is present in the solution in an amount that is equivalent to 33.0 to 66*1 g of -acetairddo-5-hydroxyacetajiddo-2,4,6-triiodobenzoic acid per 100 ml of water contained in the solution. 30* A X-ray shading system as claimed in claim 28 or 29» wherein the salt is an N-methylglucamine salt* 3†· An X-ray shading system as claimed in claim 280r 29, wherein the salt is a sodium salt, 32, An X-ray «>ia 38. An X-ray shading system as claimed in any one of claims 28 to 37, wherein the instructions comprise instructions for the administration of the aqueous solution in urography, angiography or myelography* 39. An X-ray shading system as claimed in claim 28,wherein the water-soluble salt is in the form of a preparation substantially as described in Example 3 or 4 herein. Agent for Applicant Wol ff , Bregmarv and Gol l e by: >jM^
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2118219A DE2118219C3 (en) | 1971-04-10 | 1971-04-10 | New X-ray contrast medium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL39167A0 IL39167A0 (en) | 1972-06-28 |
| IL39167A true IL39167A (en) | 1976-01-30 |
Family
ID=5804754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL39167A IL39167A (en) | 1971-04-10 | 1972-04-10 | X-ray shading agents containing a water soluble salt of 3-acetamido-5-hydroxy-acetamido-2,4,6-triiodobenzoic acid |
Country Status (15)
| Country | Link |
|---|---|
| AT (2) | AT316523B (en) |
| AU (1) | AU463194B2 (en) |
| BE (1) | BE781889A (en) |
| CA (1) | CA987339A (en) |
| CH (1) | CH574740A5 (en) |
| DD (1) | DD95265A5 (en) |
| DE (1) | DE2118219C3 (en) |
| ES (1) | ES401603A1 (en) |
| FR (1) | FR2132810B1 (en) |
| GB (1) | GB1391843A (en) |
| HU (1) | HU163446B (en) |
| IL (1) | IL39167A (en) |
| IT (1) | IT1048929B (en) |
| NL (1) | NL7204789A (en) |
| ZA (1) | ZA722396B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH641682A5 (en) * | 1978-10-05 | 1984-03-15 | Daeniker Felix | X-ray contrast medium |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3076024A (en) * | 1954-02-19 | 1963-01-29 | Sterling Drug Inc | Acylated 3, 5-diaminopolyhalobenzoic acids |
| DE1129260B (en) * | 1961-05-12 | 1962-05-10 | Schering Ag | X-ray contrast media |
-
1971
- 1971-04-10 DE DE2118219A patent/DE2118219C3/en not_active Expired
-
1972
- 1972-03-30 IT IT22619/72A patent/IT1048929B/en active
- 1972-03-30 AU AU40633/72A patent/AU463194B2/en not_active Expired
- 1972-04-06 CH CH503472A patent/CH574740A5/xx not_active IP Right Cessation
- 1972-04-07 AT AT304472A patent/AT316523B/en not_active IP Right Cessation
- 1972-04-07 DD DD162148A patent/DD95265A5/xx unknown
- 1972-04-07 HU HUSCHE385*1A patent/HU163446B/hu unknown
- 1972-04-07 AT AT459173A patent/AT318801B/en not_active IP Right Cessation
- 1972-04-08 ES ES401603A patent/ES401603A1/en not_active Expired
- 1972-04-10 IL IL39167A patent/IL39167A/en unknown
- 1972-04-10 BE BE781889A patent/BE781889A/en unknown
- 1972-04-10 FR FR7212450A patent/FR2132810B1/fr not_active Expired
- 1972-04-10 CA CA139,316A patent/CA987339A/en not_active Expired
- 1972-04-10 ZA ZA722396A patent/ZA722396B/en unknown
- 1972-04-10 GB GB1634672A patent/GB1391843A/en not_active Expired
- 1972-04-10 NL NL7204789A patent/NL7204789A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE2118219B2 (en) | 1980-07-03 |
| AU4063372A (en) | 1973-10-04 |
| FR2132810B1 (en) | 1975-03-14 |
| DE2118219C3 (en) | 1981-07-16 |
| BE781889A (en) | 1972-10-10 |
| AT318801B (en) | 1974-11-25 |
| AU463194B2 (en) | 1975-07-02 |
| CH574740A5 (en) | 1976-04-30 |
| HU163446B (en) | 1973-08-28 |
| DD95265A5 (en) | 1973-01-20 |
| IT1048929B (en) | 1980-12-20 |
| GB1391843A (en) | 1975-04-23 |
| CA987339A (en) | 1976-04-13 |
| AT316523B (en) | 1974-07-10 |
| ZA722396B (en) | 1972-12-27 |
| DE2118219A1 (en) | 1972-10-26 |
| NL7204789A (en) | 1972-10-12 |
| FR2132810A1 (en) | 1972-11-24 |
| IL39167A0 (en) | 1972-06-28 |
| ES401603A1 (en) | 1975-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1117013A (en) | Method for treating kidney stones | |
| US4690823A (en) | Ibuprofen-containing soft gelatin capsules and process for preparing same | |
| JP3678745B2 (en) | Gelatin capsule containing high concentration acetaminophen solution | |
| DE60126433T2 (en) | PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR USE WITH WEICHGELATINE FORMULATIONS | |
| JPS63145239A (en) | Medicine containing metal-containing complex compounds suitable for nmr- , x ray- , supersonic- and radiation diagnostics and therapy and manufacture of same | |
| HRP920192A2 (en) | Pharmaceutical composition suitable for influencing the reticuloendothelial system and for treating mucoviscidosis and chronic pain syndromes deriving from degenerative locomotor diseases or accompanying the diseases of tumorous origin | |
| KR20150028239A (en) | Aqueous pectin solution | |
| EP0359184B1 (en) | Etoposide solutions | |
| TWI240630B (en) | Buffered compositions for dialysis | |
| IE42950B1 (en) | Improvements in or relating to oral x-ray contrast preparations | |
| JPH0347161A (en) | Stable liquid from of 5-aminosalicyclic acid | |
| IE74244B1 (en) | A process for preparing an antibiotic composition | |
| US3794722A (en) | Iron composition for treating anemia | |
| RU2118156C1 (en) | Composition - medicinal form of antiarthrosis agent, glucosamine hydrochloride for injection | |
| JPH0687762A (en) | Preservatively stabilized glucoseamine sulfate peroral medicine and preparation thereof | |
| IL39167A (en) | X-ray shading agents containing a water soluble salt of 3-acetamido-5-hydroxy-acetamido-2,4,6-triiodobenzoic acid | |
| JP2563336B2 (en) | Eye drops for promoting corneal penetration | |
| CN101461801B (en) | Oxaliplatin medicament composition and preparation method thereof | |
| US2823163A (en) | Antivaginitis process and cation exchange resin composition | |
| EP4027977A1 (en) | Pharmaceutical composition of bimatoprost and timolol | |
| DE60120630T2 (en) | Pharmaceutical composition containing xanthan gum | |
| US3325370A (en) | Aqueous x-ray contrast composition containing a sodium salt of an iodinated organic acid and magnesium ions | |
| CN110200905A (en) | A kind of ambroxol hydrochloride composition and its injection and application | |
| Rendle-Short | Idiopathic Renal Acidosis in Twins: Alkalosis Resulting from Overdosage of a Citrate Mixture | |
| US3347746A (en) | Injectable solution of an amine salt of a radiopaque iodinated organic acid containing calcium ions |